Lung cancer, esophageal cancer, nasopharyngeal cancer
Conditions
Interventions
Experimental group:Apatinib intervention
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients meeting the approved indications for camrelizumab, including lung cancer, esophageal cancer, and nasopharyngeal carcinoma, excluding liver cancer; or cancer patients recommended by investigators as suitable for camrelizumab treatment; 2. Age >= 18 years old; 3. ECOG Score: 0-1; 4. Good function of major organs:; 4.1 Good hematopoietic function, defined as absolute neutrophil count >= 1.5×10?/L, platelet count >= 100×10?/L, hemoglobin >= 90g/L [no blood transfusion or erythropoietin dependence within 7 days]; 4.2 Good liver function, defined as total bilirubin level = 60 ml/min (Cockcroft-Gault formula); urinalysis showing less than 2+ protein; if the patient's baseline urine protein is >= 2+, 24-hour urine should be collected and 24-hour urine protein quantification should be demonstrated to be <=1g; 4.4 Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) <=1.5 times ULN; if the subject is receiving anticoagulation therapy, PT is acceptable as long as it is within the range of the anticoagulant medication intended for use; 5. For female subjects of childbearing potential, a serum pregnancy test should be performed within seven days prior to the first dose of the investigational drug (cycle 1, day 1), and the result should be negative; 6. Participants must agree to use effective methods of contraception or be surgically sterilized during the trial period and for 90 days after the last administration of the investigational drug; 7. Able to comply with research and follow-up procedures; 8. Obtain written informed consent before any trial-related procedures are implemented.
Exclusion criteria
Exclusion criteria: 1. Patients who have received other immunotherapies or treatments concurrently; 2. Patients currently participating in other interventional studies; 3. Patients who also have other malignant tumors; 4. Previous treatment with anti-angiogenic drugs; 5. Accompanied by active bleeding or perforation, or the presence of a hereditary or acquired bleeding tendency; 6. Individuals with hypertension whose blood pressure cannot be lowered to the normal range by antihypertensive medication (systolic blood pressure = (++), and 24-hour urine protein >= 1.0g; 8. Patients with thrombotic disorders who require long-term anticoagulation therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin >= 300 mg/day or clopidogrel >= 75 mg/day); 9. It has many factors that affect the absorption of oral medications, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction; 10. Has a known history of human immunodeficiency virus (HIV) infection; 11. An active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying medications, corticosteroids, or immunosuppressants) occurred within 2 years prior to the first dose. Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment; 12. Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study; use of physiological doses of glucocorticoids (= 470 ms for women). Subjects with NYHA grade III-IV heart failure or those with LVEF (left ventricular ejection fraction = 2.5 mL within one month prior to the first dose of medication; 16. Nasopharyngeal carcinoma: Excluding radiation-induced nasopharyngeal necrosis; 17. Individuals deemed unsuitable for apatinib by researchers after comprehensive evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median duration of RCCEP (from onset to resolution); | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;Median Time to Remission with RCCEP;Incidence of Grade 1/2/3 RCCEP; | — |
Countries
China
Contacts
Public ContactZhao Zhigang
Tianjin First Central Hospital
Outcome results
None listed